The implications of these results underscore OC’s promise as a targeted therapeutic agent for inflammation-driven oncogenic pathways in CRC, particularly through its specificity in modulating PAR-2 without affecting related GPCRs, such as PAR-1 (Figure 3). This evidence concerns the gene F2RL1 and colorectal carcinoma.